Circulatory system

New medical software aids diagnosis of autoimmune diseases with AI

Wednesday, September 23, 2020 - 4:00pm

By looking at capillaries, doctors can assess the health of the patient's blood circulation, find abnormal capillaries, capillary loss, etc.

Key Points: 
  • By looking at capillaries, doctors can assess the health of the patient's blood circulation, find abnormal capillaries, capillary loss, etc.
  • which can lead to conditions such as scleroderma and dermatomyositis.
  • Capillary.io is a new tool that improves capillaroscopy efficiency, objectiveness and boosts research by using AI to automatically detect, measure and classify capillaries by its shape and size, and also give useful and comprehensive metrics to doctors.
  • We can obtain reports with clinical parameters quickly and easily that guide us in the diagnosis, for example, of diseases such as scleroderma, by studying the microcirculation of the capillaries near the base of the patient's nail".

Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation

Monday, September 21, 2020 - 2:02pm

ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its fourth-generation MitraClip Transcatheter Mitral Valve Repair System, the leading minimally invasive mitral valve repair device in the world.

Key Points: 
  • ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its fourth-generation MitraClip Transcatheter Mitral Valve Repair System, the leading minimally invasive mitral valve repair device in the world.
  • Known as MitraClip G4, the device is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical option for the treatment of mitral regurgitation (MR), or a leaky heart valve.
  • While medication can help people manage the symptoms of MR, it does not treat the leaky valve itself.
  • Once in place, MitraClip restores the proper functioning of the mitral valve and the heart's ability to pump oxygenated blood more efficiently.

DGAP-News: 4TEEN4's first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis

Wednesday, September 16, 2020 - 9:01am

The study data (1) from the team lead by Prof. Alexandre Mebazaa have shown that high DPP3 blood values are associated with decreased heart function in a preclinical sepsis model.

Key Points: 
  • The study data (1) from the team lead by Prof. Alexandre Mebazaa have shown that high DPP3 blood values are associated with decreased heart function in a preclinical sepsis model.
  • In this randomized, controlled study, the administration of Procizumab immediately and significantly improved heart function by increasing cardiac output, stroke volume, and left ventricular shortening fraction.
  • By inhibiting DPP3 with our antibody Procizumab, we are able to restore cardiac function in preclinical sepsis models.
  • This inactivation leads to cardiac depression and consequently hemodynamic instability and consequently cardiac depression.

Low awareness of serious but treatable heart condition could be putting Canadian lives at risk

Tuesday, September 15, 2020 - 3:27pm

TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Survey results published by Global Heart Hub show that older Canadians are as unaware as ever of aortic stenosis, the most common form of heart valve disease.

Key Points: 
  • TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Survey results published by Global Heart Hub show that older Canadians are as unaware as ever of aortic stenosis, the most common form of heart valve disease.
  • The survey demonstrates that more needs to be done to raise awareness of heart valve disease and the importance of an annual stethoscope check for those most likely to suffer.
  • It is estimated that by the age of 75, the prevalence of heart valve disease is 13%iv, putting the senior population more at risk as they grow older.
  • It is a common, serious, but treatable condition which is particularly associated with ageing.

Shockwave Coronary IVL U.S. Pivotal Study Results to be Presented in Late-Breaking Session at TCT Connect

Tuesday, September 15, 2020 - 1:00pm

The webcast event will include remarks from Dr. Dean Kereiakes as well an interactive question and answer session with a panel of experts.

Key Points: 
  • The webcast event will include remarks from Dr. Dean Kereiakes as well an interactive question and answer session with a panel of experts.
  • Shockwave C2 Coronary IVL catheters are commercially available for the treatment of de novo coronary artery disease in Europe and select other geographies; they are limited to investigational use in the United States.
  • DISRUPT CAD III is a prospective, multicenter, single-arm, global IDE study designed to demonstrate the safety and effectiveness of the Shockwave Coronary IVL System with the Shockwave C2 Coronary IVL Catheter in de novo, calcified, stenotic, coronary arteries prior to stenting.
  • The study enrolled 384 patients, exceeding the minimum requirement of 372 patients, per the a priori statistical plan agreed by the FDA.

Abiomed to Hold Fireside Chat at the Raymond James North American Equities Conference

Monday, September 14, 2020 - 12:00pm

(NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Raymond James North American Equities Conference (virtual) on Thursday, September 17th, 2020 at 10:30 am ET.

Key Points: 
  • (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Raymond James North American Equities Conference (virtual) on Thursday, September 17th, 2020 at 10:30 am ET.
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.
  • Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
  • Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.

North America Implantable Loop Recorders (Atrial fibrillation, Cardiac Arrhythmia and Cardiac Syncope) Market 2020-2026 - ResearchAndMarkets.com

Monday, September 14, 2020 - 10:17am

The "North America Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac Centers and Other End Users), By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac Centers and Other End Users), By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The implantable cardiac device continues to continuously monitor the heart, contributing to the diagnosis of chronic heart problems such as stroke and heart failure.
  • Early identification by implantable cardiac monitors boost demand for implantable cardiac monitors (ICMs) and provide more successful results than external cardiac monitors.
  • The growth in the number of patients suffering from chronic disorders, including stroke and cardiac failure, is pushing the demand for implantable loop recorders.

Kardium Marks First Commercial Procedures of Globe® Mapping and Ablation System

Tuesday, September 8, 2020 - 5:00pm

Kardium Inc. announced the first commercial procedures with the Globe Mapping and Ablation System .

Key Points: 
  • Kardium Inc. announced the first commercial procedures with the Globe Mapping and Ablation System .
  • View the full release here: https://www.businesswire.com/news/home/20200908005275/en/
    From right to left: Prof. Hans Kottkamp (Sana Hospital Benrath in Dsseldorf), Ashkan Sardari (Project Manager, Kardium), and Nele Thoms (Field Clinical Specialist, Kardium) during the first commercial procedure with the Globe Mapping and Ablation System.
  • Approval of the Globe System was based on the positive results from the GLOBAL-AF study , a multi-centre study that demonstrated the safety and effectiveness of the Globe Mapping and Ablation System.
  • Kardium Inc. ( kardium.com ) is a rapidly growing medical solutions company that has developed an advanced system for the treatment of atrial fibrillation: the Globe Mapping and Ablation System.

Abiomed to Hold Fireside Chat at the 18th Annual Morgan Stanley Global Healthcare Conference

Tuesday, September 8, 2020 - 12:00pm

(NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference (virtual) on Tuesday, September 15th, 2020 at 2:45pm ET.

Key Points: 
  • (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference (virtual) on Tuesday, September 15th, 2020 at 2:45pm ET.
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.
  • Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
  • Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Center for Vein Restoration Committed to Peer-to-Peer Education and Increasing Awareness of CVI

Tuesday, September 8, 2020 - 11:00am

GREENBELT, Md., Sept. 8, 2020 /PRNewswire-PRWeb/ -- Center for Vein Restoration (CVR) concluded their National Summer Series of free 1.0 category one Continuing Medical Education (CME) credit webinars on August 20, 2020.

Key Points: 
  • GREENBELT, Md., Sept. 8, 2020 /PRNewswire-PRWeb/ -- Center for Vein Restoration (CVR) concluded their National Summer Series of free 1.0 category one Continuing Medical Education (CME) credit webinars on August 20, 2020.
  • Topics ranged from lymphedema to leg pain, but all centered on diagnosing and treating one underlying cause: Chronic Venous Insufficiency (CVI).
  • Accredited CME offerings presented by CVR physicians have long been a cornerstone of CVR's commitment to education.
  • Center for Vein Restoration (CVR) is the largest physician-led practice treating vein disease in the country.